Annals of Hematology

, Volume 69, Issue 1, pp 25–31 | Cite as

Interleukin-6 production in B-cell neoplasias and Castleman's disease: Evidence for an additional paracrine loop

  • R. Burger
  • J. Wendler
  • K. Antoni
  • G. Helm
  • J. R. Kalden
  • M. Gramatzki
Original Article


Functioning as a B-cell growth and differentiation factor, interleukin-6 (IL-6) may play an important role in the pathophysiology of B-cell tumors. The capacity for IL-6 secretion was evaluated in 58 patients with various B-cell leukemias/lymphomas and in four patients with Castleman's disease (CMD). Cell populations from various sites including peripheral blood, bone marrow, lymph nodes, and osteolytic bone lesions were cultured and tested for spontaneous or IL-1Β/ TNFα-induced IL-6 production in a sensitive bioassay. No significant IL-6 levels were released by the tumor cells in any of the B-cell leukemias or lymphomas tested, including hairy cell leukemia (HCL) and B-cell chronic lymphocytic leukemia (B-CLL). In contrast, purified malignant plasma cells were found to secrete IL-6, strengthening the idea that an autocrine pathway for growth regulation in multiple myeloma (MM) exists. For the first time, in several patients with CMD, peripheral blood cells were shown to produce extremely high levels of IL-6, the pathogenetic significance of which remains to be elucidated. However, similar observations were very occasionally made in MM patients. Therapy with corticosteroids strongly inhibited this IL-6 production. These data provide evidence for autocrine and possibly an additional paracrine regulatory loop in plasma cell neoplasias and CMD.

Key words

Interleukin-6 Castleman's diesease Multiple myeloma Leukemia Lymphoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aarden LA, De Groot ER, Schaap OL, Lansdorp PM (1987) Production of hybridoma growth factor by human monocytes. Eur J Immunol 17:1411–1416Google Scholar
  2. 2.
    Aguilar-Santelises M, Magnusson R, Svenson SB, Loftenius A, Andersson B, Mellstedt H, Jondal M (1991) Expression of interleukin-1α, interleukin-1Β and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression. Clin Exp Immunol 84:422–428Google Scholar
  3. 3.
    Asano S, Okano A, Ozawa K, Nakahata T, Ishibashi T, Koike K, Kimura H, Tanioka Y, Shibuya A, Hirano T, Kishimoto T, Takaku F, Akiyama Y (1990) In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood 75:1602–1605Google Scholar
  4. 4.
    Bauer J, Ganter U, Geiger T, Jacobshagen U, Hirano T, Matsuda T, Kishimoto T, Andus T, Acs G, Gerok W, Ciliberto G (1988) Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte-derived macrophages. Blood 72:1134–1140Google Scholar
  5. 5.
    Beck JT, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B (1994) Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602–605Google Scholar
  6. 6.
    Biondi A, Rossi V, Bassan R, Barbui T, Bettoni S, Sironi M, Mantovani A, Rambaldi A (1989) Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood 73:1279–1284Google Scholar
  7. 7.
    Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW (1990) Dysregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86:592–599Google Scholar
  8. 8.
    Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Machisio PC (1991) Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688–2693Google Scholar
  9. 9.
    Carter A, Merchav S, Silvian-Draxler I, Tatarsky I (1990) The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma. Br J Haematol 74:424–431Google Scholar
  10. 10.
    Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlations of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854Google Scholar
  11. 11.
    Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF, Nadler LM (1989) Interleukin-6 gene expression in normal and neoplastic B cells. J Clin Invest 83:1512–1518Google Scholar
  12. 12.
    Gramatzki M, Burger R, Kraus J, Lauer U, Rohwer P, Eger G, Kalden JR, Henschke F (1991) Monoclonal antibodies EBU-141 (CDw75) and EBU-65 allow reliable distinction between mature and pre-B-cell tumors in suspension and on tissue sections. Ann Hematol 63:20–26Google Scholar
  13. 13.
    Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J (1993) Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 81:3357–3364Google Scholar
  14. 14.
    Helfgott DC, May LT, Sthoeger Z, Tamm I, Sehgal PB (1987) Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion ofΒ 2 interferon by human fibroblasts. J Exp Med 166:1300–1309Google Scholar
  15. 15.
    Heslop HE, Bianchi ACM, Cordingley FT, Turner M, De Mel WCP, Hoffbrand AV, Brenner MK (1990) Effects of interferonα on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med 172:1729–1734Google Scholar
  16. 16.
    Hirano T, Akira S, Taga T, Kishimoto T (1990) Biological and clinical aspects of interleukin 6. Immunol Today 11:443–449Google Scholar
  17. 17.
    Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M, Kuramoto A (1990) Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1Β osteoclast activating factor-induced bone resorption. Blood 75:715–720Google Scholar
  18. 18.
    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85Google Scholar
  19. 19.
    Kawano M, Tanaka H, Ishikawa H, Nobuyoshi M, Iwato K, Asaoku H, Tanabe O, Kuramoto A (1989) Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 73:2145–2148Google Scholar
  20. 20.
    Kawano M, Yamamoto I, Iwato K, Tanaka H, Asaoku H, Tanabe O, Ishikawa H, Nobuyoshi M, Ohmoto Y, Hirai Y, Kuramoto A (1989) Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 73:1646–1649Google Scholar
  21. 21.
    Kishimoto T (1989) The biology of interleukin-6. Blood 74:1–10Google Scholar
  22. 22.
    Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J, Bataille R (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198–1204Google Scholar
  23. 23.
    Klein B, Zhang X-G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517–526Google Scholar
  24. 24.
    Lahat N, Aghai E, Maroun B, Kinarty A, Quitt M, Froom P (1991) Increased spontaneous secretion of IL-6 from B cells of patients with B chronic lymphatic leukaemia (B-CLL) and autoimmunity. Clin Exp Immunol 85:302–306Google Scholar
  25. 25.
    Lang RA, Burgess W (1990) Autocrine growth factors and tumourigenic transformation. Immunol Today 11:244–249Google Scholar
  26. 26.
    Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D (1991) Interleukin-6 gene expression in Castleman's disease. Blood 78:2923–2930Google Scholar
  27. 27.
    Sporn MB, Roberts AB (1985) Autocrine growth factors and cancer. Nature 313:745–747Google Scholar
  28. 28.
    Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van Unnik JAM, Mioduszewska O, Wright DH (1988) Updated Kiel classification for lymphomas. Lancet 1:292–293Google Scholar
  29. 29.
    Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 86:7547–7551Google Scholar
  30. 30.
    Tobler A, Meier R, Scitz M, Dewald B, Baggiolini M, Fey MF (1992) Glucocorticoids downregulate gene expression of GMCSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 79:45–51Google Scholar
  31. 31.
    Van Damme J, Opdenakker G, Simpson RJ, Rubira MR, Cayphas S, Vink A, Billiau A, Van Snick J (1987) Identification of the human 26-kD protein, interferonΒ 2 (IFN-Β 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 165:914–919Google Scholar
  32. 32.
    Van Snick J, Vink A, Cayphas S, Uyttenhove C (1987) Interleukin-HP1, a T-cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J Exp Med 165:641–649Google Scholar
  33. 33.
    Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donckers D, Van Snick J (1990) Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med 172:997–1000Google Scholar
  34. 34.
    Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, Levin R, Rosenberg SA (1993) Phase-I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 11:499–506Google Scholar
  35. 35.
    Wendler J, Burger R, Stö\ H, Becker W, Feller AC, Kalden JR, Gramatzki M (1991) B-cell angiotropic lymphoma with bone involvement and paracrine IL-6 production. Onkologie 15 [Suppl 2]:172Google Scholar
  36. 36.
    Yabuhara A, Komiyama A (1990) Castleman's disease and interleukin 6. Leukemia Lymphoma 2:369–380Google Scholar
  37. 37.
    Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahate T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto A (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74:1360–1367Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • R. Burger
    • 1
  • J. Wendler
    • 1
  • K. Antoni
    • 1
  • G. Helm
    • 1
  • J. R. Kalden
    • 1
  • M. Gramatzki
    • 1
  1. 1.Division of Hematology/Oncology, Department of Medicine IIIUniversity of ErlangenErlangenGermany

Personalised recommendations